About MEAJO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions to authors | Online submission | Subscribe | Advertise | Contact | Login 
Middle East African Journal of Ophthalmology Middle East African Journal of Ophthalmology
Users Online: 4286   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
UPDATES IN CLINICAL TRIALS IN RETINA
Year : 2016  |  Volume : 23  |  Issue : 1  |  Page : 13-26

Update on clinical trials in dry Age-related macular degeneration


1 Division of Vitreoretinal, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
2 Jeddah Eye Hospital, Jeddah, Kingdom of Saudi Arabia
3 Division of Vitreoretinal, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; Department of Ophthalmology, Clinical Sciences, Scane County University Hospital, University of Lund, Sweden

Correspondence Address:
Patrik Schatz
Vitreoretinal Division, King Khaled Eye Specialist Hospital, Al.Oruba Street, P. O. Box 7191, Riyadh 11462

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-9233.173134

Rights and Permissions

This review article summarizes the most recent clinical trials for dry age.related macular degeneration (AMD), the most common cause of vision loss in the elderly in developed countries. A literature search through websites https://www.pubmed.org and https://www.clinicaltrials.gov/, both accessed no later than November 04, 2015, was performed. We identified three Phase III clinical trials that were completed over the recent 5 years Age.Related Eye Disease Study 2 (AREDS2), implantable miniature telescope and tandospirone, and several other trials targeting a variety of mechanisms including, oxidative stress, complement inhibition, visual cycle inhibition, retinal and choroidal blood flow, stem cells, gene therapy, and visual rehabilitation. To date, none of the biologically oriented therapies have resulted in improved vision. Vision improvement was reported with an implantable mini telescope. Stem cells therapy holds a potential for vision improvement. The AREDS2 formulas did not add any further reduced risk of progression to advanced AMD, compared to the original AREDS formula. Several recently discovered pathogenetic mechanisms in dry AMD have enabled development of new treatment strategies, and several of these have been tested in recent clinical trials and are currently being tested in ongoing trials. The rapid development and understanding of pathogenesis holds promise for the future.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed10783    
    Printed326    
    Emailed0    
    PDF Downloaded547    
    Comments [Add]    

Recommend this journal